FDA cleared its second new molecular entity of the year, UCB Pharma SA's Briviact, to cap a week otherwise dominated by news of novel products not receiving approval.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?